March 14, 2008 |
In mixed news for biotech giant Amgen Inc., a Food and Drug Administration panel recommended Thursday that doctors continue to prescribe the company's lucrative anemia drugs for patients with cancer. But the panel suggested scaling back which patients should be treated based on their type of cancer and the severity of the disease. The recommendations could lead to further sales declines in the company's blockbuster drug Aranesp. Thousand Oaks-based Amgen makes an identical product that is sold under the name Procrit by Johnson & Johnson.
March 8, 2008 |
Drug maker Amgen Inc. said regulators had added new warnings about the risks of death and tumor growth to the Thousand Oaks company's blockbuster anemia drugs. The warnings approved by the Food and Drug Administration say that Aranesp and Epogen increased the likelihood of death and accelerated tumor growth in patients with several types of cancer, including breast and cervical. The warnings also apply to Johnson & Johnson's drug Procrit.
February 6, 2008 |
Amgen Inc. must defend a lawsuit over claims that it misled investors about safety issue with its top-selling anemia drugs, Epogen and Aranesp. A U.S. district judge in Los Angeles denied Amgen's request to dismiss a consolidated shareholders' complaint. Shareholders say Thousand Oaks-based Amgen artificially inflated its stock price from April 2004 to May 2007 by making false statements about the drugs' safety and by marketing them for uses not approved by the Food and Drug Administration.
November 13, 2007 |
Amgen Inc. said it received two federal subpoenas in the last month seeking documents about its products. One subpoena came from the U.S. attorney's office for the Eastern District of New York on Oct. 25, and the other from the U.S. attorney's office for the Western District of Washington on Nov. 1, the Thousand Oaks-based company disclosed in a regulatory filing Friday. The filing doesn't say which products are involved.
July 27, 2007 |
Beleaguered biotech giant Amgen Inc. on Thursday reported a surprisingly steep drop in sales of its main anemia product line, raising doubts about the company's growth prospects. But the Thousand Oaks-based firm's profit remained substantial on stronger-than-expected sales of other products. Revenue increased 3% during the second quarter to $3.7 billion, versus $3.6 billion last year. Profit rose 2% to $1.3 billion, compared with $1.2 billion in the second quarter of 2006.
April 24, 2007 |
Amgen Inc. on Monday reported an 11% rise in first-quarter profit, driven by increased sales of its anemia and arthritis drugs. But the company said its earnings per share for fiscal 2007 would be at the low end of its previous forecast. Recent safety questions cut into sales growth of the company's bestselling product, anemia drug Aranesp, the Thousand Oaks-based company said. But Amgen also reported progress on its most promising new drug, osteoporosis treatment denosumab.
April 20, 2007 |
Whose responsibility is it to ensure a product sold to millions of Americans is safe? In the drug industry, it's no simple question. Take, for example, the case of Amgen Inc. The Thousand Oaks biotech giant Thursday released the results of a highly anticipated safety study of the company's popular anemia drug Aranesp, which along with similar anemia medications is taken by more than a million people in the U.S. each year.
October 20, 2005 |
Biotechnology giant Amgen Inc. reported sharply higher third-quarter earnings Wednesday, led by sales of its anemia drug Aranesp. The Thousand Oaks-based company had earnings of $967 million, or 77 cents a share, compared with $236 million, or 18 cents, for the year-earlier quarter, when results where hurt by charges related to the acquisition of Tularik Inc. of South San Francisco. Revenue increased 16% to $3.2 billion from $2.6 billion in the third quarter of 2004.
November 17, 2003 |
What is now a contest between Amgen Inc. and Johnson & Johnson over the lucrative anemia drug business could soon become a three-way race. At a medical meeting here this weekend, Swiss drug maker Roche said it was ready to begin the final round of human tests needed for government approval of Cera, its investigational anemia drug.
November 16, 2002 |
Moving to protect its turf against archrival Johnson & Johnson in the lucrative market for anemia treatments, Amgen Inc. on Friday sued the federal government for slashing the Medicare reimbursement rate on its drug Aranesp. The suit, filed in U.S. District Court in Washington, seeks an injunction to prevent the rate cut, which would make Aranesp more expensive for hospital outpatient treatment than the Johnson & Johnson anemia drug Procrit.